Nrx Pharmaceuticals shares rise 1.19% after-hours following AHCA approval for Dura Medical acquisition.

Nrx Pharmaceuticals, Inc. rose 1.19% in after-hours trading, following the announcement that HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, has received approval from Florida's Agency for Health Care Administration (AHCA) for the acquisition of Dura Medical. This acquisition, along with previously announced acquisitions of Neurospa TMS and Cohen and Associates, is expected to expand coverage along the West Coast of Florida and provide a full range of precision psychiatry services for severe depression, PTSD, and related CNS disorders. The acquisition is anticipated to be accretive to revenue and EBITDA.